P&G's Prilosec goes deep on social media

Share this article:
P&G's Prilosec goes deep on social media
P&G's Prilosec goes deep on social media
Procter & Gamble is launching a social media initiative for Prilosec as part of its bid to maintain the PPI's leadership position in a crowded market.

Dubbed “Official Sponsor of Everything You Do Without Heartburn,” the contest invites consumers to post videos and stories making their case for items—such as cameras, classes or guitars—worth an average of $1,000 that will help them pursue their passions. Entrants can submit for 15 categories, including arts and crafts, sports, health and fitness and community service and volunteerism.

Visitors to the site, officialsponsor.com can register to vote for their favorites, and winners, to be determined by fan votes and a panel, will be announced in March and May. A Facebook fan page and Twitter handle provide program updates and details

Bridge Worldwide designed the site and MS&L is handling PR on the campaign.  

In November, P&G launched a smilar campaign incorporating digital, PR, advertising and retail with its Madden Most Valuable Protector's Award. Sponsored by the brand in partnership with the NFL and John Madden, the award honors the NFL's best offensive lineman—again based on fan voting and an expert panel—and will be presented at this year's Super Bowl.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...